# A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)

> **NCT04608838** · PHASE1,PHASE2 · COMPLETED · sponsor: **Teijin Pharma Limited** · enrollment: 79 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **BIOLOGICAL:** JTR-161
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04608838
- **Lead sponsor:** Teijin Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-30
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-11-24
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608838, "A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT04608838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*